LakeShore Biopharma Gets Nasdaq Delisting Notification

Written by Emily J. Thompson, Senior Investment Analyst

LSB%

Updated: Sep 12 2025

0mins

Nasdaq Compliance Notification: LakeShore Biopharma received a determination letter from Nasdaq stating it is not in compliance with Listing Rule 5550(a)(2) due to its ordinary shares closing below $1.00 for 30 consecutive business days.
Delisting Consequences: The company is ineligible for the standard 180-day compliance period because it executed a reverse stock split within the past year, leading to a decision to delist its securities effective September 22, 2025, unless an appeal is filed.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

LakeShore Biopharma Gets Nasdaq Delisting Notification

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Quantum Computing (QUBT) Stock Falls 38% in 2025, Acquires Luminar Semiconductor to Boost Recovery

Robinhood (HOOD) Stock Soars 1,100% but Faces Market Risks

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch